Kyoungmin Lee
Overview
Explore the profile of Kyoungmin Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
376
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Jeong H, Cho H, Kim H, Chae H, Lee J, Lee K, et al.
Blood Adv
. 2021 Apr;
5(8):2142-2152.
PMID: 33881464
Despite central nervous system (CNS) relapse occurring in >10% of high-risk diffuse large B-cell lymphoma (DLBCL) patients, the role of CNS-directed prophylaxis is controversial in the absence of randomized controlled...
22.
Lee K, Sim S, Joo Kang E, Seo J, Chae H, Lee K, et al.
Front Oncol
. 2021 Mar;
11:653243.
PMID: 33747970
The role of chemotherapy for isolated locoregional recurrence (iLRR) of breast cancer has not been firmly established after local therapies. We performed a multicenter, retrospective analysis to evaluate the clinical...
23.
Lee K, Kim D, Yoon S, Lee D, Kim S
Eur J Cancer
. 2021 Mar;
148:202-210.
PMID: 33744716
Introduction: Although osimertinib overcomes the T790M mutation acquired after traditional epidermal growth factor receptor (EGFR) gene tyrosine kinase inhibitor (TKI) treatment, resistance to osimertinib eventually occurs. We explored resistance mechanisms...
24.
Kim H, Cho H, Kim S, Lee K, Kang E, Park J, et al.
Cancer Res Treat
. 2020 Dec;
53(3):847-856.
PMID: 33332932
Purpose: We aimed to investigate the prognostic value of serum β2-microglobulin for patients with Burkitt lymphoma (BL) and to propose a risk-stratifying classification system. Materials And Methods: A prospective registry-based...
25.
Kim H, Cho H, Jeong H, Bang K, Kim S, Lee K, et al.
Br J Haematol
. 2020 Nov;
193(2):307-315.
PMID: 33216979
The mucosa-associated lymphoid tissue (MALT) International Prognostic Index (IPI) was recently proposed as a prognostic index for patients with MALT lymphoma. We aimed to investigate the prognostic value of the...
26.
Lee K, Koo H, Kim Y, Kim D, Son E, Yang H, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33142709
We aimed to evaluate the preclinical efficacy of GC1118, a novel anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), against glioblastoma (GBM) tumors using patient-derived xenograft (PDX) models. A total...
27.
Lee K, Ha J, Jung A, Lee Y, Lee S, Ryu J, et al.
Leuk Lymphoma
. 2020 Apr;
61(7):1575-1583.
PMID: 32290739
We evaluated real-world effectiveness and safety of CT-P10 (Truxima) compared with originator rituximab in diffuse large B-cell lymphoma (DLBCL) treatment. Before and after the introduction of CT-P10 to our institute...
28.
Lee K, Song J, Kim J, Kim W, Song S, Lee M, et al.
Eur J Surg Oncol
. 2020 Mar;
46(7):1287-1293.
PMID: 32127249
Introduction: Little is known about undifferentiated pleomorphic sarcoma (UPS) because of the low incidence and heterogeneous diagnosis of sarcoma. We investigated the oncologic outcomes of patients with UPS in a...
29.
Lee H, Son E, Lee K, Lee Y, Kim Y, Lee J, et al.
Int J Mol Sci
. 2019 Nov;
20(23).
PMID: 31771279
Epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies, including cetuximab and panitumumab, are used to treat metastatic colorectal cancer (mCRC). However, this treatment is only effective for a small subset of...
30.
Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations
Choi J, Yoon S, Kim D, Moon Y, Lee C, Seo S, et al.
Am J Cancer Res
. 2019 Sep;
9(8):1708-1721.
PMID: 31497352
The non-small cell lung cancer (NSCLC) patients with EGFR-sensitive mutations can be therapeutically treated by EGFR-TKI such as erlotinib and gefitinib. However, about 40% of individuals harboring EGFR-TKI sensitive mutations...